IPP Bureau
Thyrocare Technologies posts Q1FY23 consolidated PAT at Rs. 21.73 Cr
By IPP Bureau - August 02, 2022
The company has reported total income of Rs. 128.79 crores during the period ended June 30, 2022.
Statement from Krsnaa Diagnostics on IT survey
By IPP Bureau - August 02, 2022
The news report stating Krsnaa Diagnostics has accepted Rs 100 crores of undisclosed income is incorrect and baseless.
UBC acquires Examoto
By IPP Bureau - August 02, 2022
With this acquisition, UBC provides the most comprehensive REMS services and innovative risk mitigation solutions for the biopharmaceutical industry
Ayush Minister Sonowal inaugurates Ayush Building Complex in Navi Mumbai
By IPP Bureau - August 01, 2022
Steps afoot to make RRIH & RRIUM as a Centres of Excellence for Allergic Disorder and for Regimental Therapy respectively
Casper Pharma completed USFDA pre-approval inspection
By IPP Bureau - July 31, 2022
The audit is part of the agency's inspection for three product applications filed and slated to be manufactured at this site.
Shilpa Medicare's Unit III, Advanced Analytical Characterization Laboratory clears US FDA remote record review
By IPP Bureau - July 31, 2022
The facility is designed with advanced analytical equipment to provide testing services such as In-vitro Permeation testing
Cipla posts Q1FY23 consolidated PAT at Rs. 686.40 Cr
By IPP Bureau - July 31, 2022
he company has reported total income of Rs. 5478.62 crores during the period ended June 30, 2022.
Torrent Pharmaceuticals posts Q1FY23 consolidated PAT Rs. 354 Cr
By IPP Bureau - July 31, 2022
Torrent Pharmaceuticals has reported total income of Rs. 2377 crores during the period ended June 30, 2022.
Cariflex breaks ground on world's largest polyisoprene latex plant in Singapore
By IPP Bureau - July 29, 2022
Driven by a strong commitment to better serve its global customers in medical and consumer products, this investment represents the largest capacity expansion in Cariflex’s existing accomplishments
Alniche Lifesciences celebrates 15 anniversary
By IPP Bureau - July 29, 2022
The company is focused on therapies such as skinceuticals, gastroenterology, neuropsychiatry, cardiac diabetes care etc.
GMM Pfaudler Q1FY23 consolidated PAT surges to Rs. 44.51 Cr
By IPP Bureau - July 29, 2022
GMM Pfaudler has reported total income of Rs. 767.73 crores during the period ended June 30, 2022
Biocon Q1FY23 consolidated PAT falls QoQ at Rs. 144.4 Cr
By IPP Bureau - July 28, 2022
Biocon has reported total income of Rs. 2217.4 crores during the period ended June 30, 2022.
Novartis India Q1FY23 PAT jumps to Rs. 52.38 Cr
By IPP Bureau - July 28, 2022
Novartis India has reported total income of Rs. 147.44 crores during the period ended June 30, 2022.















